Recombinant protein · Inhibitor of Plasma kallikrein (KLKB1), Complement C1r (C1R) and Complement C1s (C1S) · developed by Pharming Healthcare
C1 esterase inhibitor [recombinant] is a recombinant form of the human C1 esterase inhibitor protein, which regulates the complement and contact systems. It is studied in hereditary angioedema and angioedema, and in confirmed coronavirus disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 30, 2020). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01188564 | Phase 3 | Hereditary Angioedema | Completed | PHAR |
| NCT00225147 | Phase 2/3 | Hereditary Angioedema | Completed | PHAR |
| NCT04530136 | Phase 2 | Confirmed Coronavirus Disease | Completed | PHAR |
| NCT01426763 | Phase 2 | Hereditary Angioedema | Completed | HALO |
| NCT01397864 | N/A | Hereditary Angioedema | Completed | PHAR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Angioneurotic EdemaConfirmed Coronavirus DiseaseHereditary Angioedema
Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.
See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PHAR catalysts and pipeline →